Vanda Pharmaceuticals Inc. (VNDA)
After hours:
| Previous Close | 4.4800 |
| Open | 4.5000 |
| Bid | 4.6000 x 500 |
| Ask | 4.6300 x 500 |
| Day's Range | 4.4500 - 4.6250 |
| 52 Week Range | 3.3000 - 7.0000 |
| Volume | |
| Avg. Volume | 2,332,936 |
| Market Cap | 265.823M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | 115.50 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Reminds Vanda’s Board of Their Fiduciary Duties Given the Mishandling of Future Pak’s Offer to Acquire Vanda’s Underperforming and Undervalued Shares at an ~80-90% Premium Expresses Serious Concerns Over Entrenchment, Misaligned Incentives, and Cronyism at Vanda, Including the CEO’s and His Family’s $46M+ in Disclosed Compensation Amidst $1B+ in Shareholder Value Destruction Believes Vanda’s Board Must Explore Strategic Alternatives MIAMI, April 25, 2024 (GLOBE NEWSWIRE) -- Shareholder Capital L
- PR Newswire
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
- PR Newswire
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect stockholder interests and maximize value for all stockholders. The Rights Plan is effective immediately.
